Hikma expands injectables capacity with acquisition of Xellia's US assets
06/20/24, 1:10 PM
Location
london
denmarkIndustry
manufacturing
Hikma, a London-based generics maker, has agreed to acquire parts of Xellia's U.S. assets, including the manufacturing facility in Cleveland. The acquisition will bolster Hikma's U.S. injectable manufacturing capabilities and portfolio, adding significant scale to its operations and complex technologies. This strategic move is part of Hikma's commitment to enhancing its productivity, expanding into the CDMO business, and strengthening its position in the market.
Company Info
Location
London, Ontario, Canada
Company info
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, they've been creating high-quality medicines and making them accessible. Headquartered in the UK, Hikma has a global presence and focuses on transforming cutting-edge science into innovative solutions. Their range includes both branded and non-branded generic medicines.